<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Belumosudil: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Belumosudil: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Belumosudil: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="132098" href="/d/html/132098.html" rel="external">see "Belumosudil: Drug information"</a> and <a class="drug drug_patient" data-topicid="132114" href="/d/html/132114.html" rel="external">see "Belumosudil: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56021542"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Rezurock</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F58086350"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Rezurock</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F55989464"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">ROCK2 Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F56021560"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ae6a0a8-6a6c-4253-b5ff-2afe6b76558b">Graft-versus-host disease, chronic, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease (GVHD), chronic, treatment: </b>Children ≥12 years and Adolescents: Oral: 200 mg once daily until progression of chronic GVHD that requires new systemic therapy or until unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34265047']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34265047'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage </b>
<b>adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Grade 3 adverse reactions: </i>Withhold belumosudil until recovery to grade 0 to 1, then resume belumosudil at recommended dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Grade 4 adverse reactions: </i>Permanently discontinue belumosudil.</p></div>
<div class="block dorp drugH1Div" id="F56021561"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">GFR ≥30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically meaningful differences in belumosudil pharmacokinetics were observed in mild and moderate kidney impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Consider the risks versus the potential benefits of belumosudil prior to initiating therapy in patients with severe kidney impairment.</p></div>
<div class="block dohp drugH1Div" id="F56021562"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline hepatic impairment: </i>There are no dosage adjustments provided in the manufacturer's labeling. Consider the risks versus the potential benefits of initiating belumosudil in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Grade 3 AST or ALT (5 to 20 times ULN) <b>or </b>grade 2 bilirubin (1.5 to 3 times ULN): Withhold belumosudil until recovery of AST, ALT, and bilirubin to grade 0 to 1, then resume belumosudil at recommended dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4 AST or ALT (&gt;20 times ULN) <b>or</b> ≥ grade3 bilirubin (&gt;3 times ULN): Permanently discontinue belumosudil.</p></div>
<div class="block doa drugH1Div" id="F56042836"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="132098" href="/d/html/132098.html" rel="external">see "Belumosudil: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fe113e98-19c6-4d7f-8e42-965ede803185">Graft-versus-host disease, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, chronic: Oral:</b> 200 mg once daily until progression of chronic graft-vs-host disease that requires new systemic therapy or until unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34265047']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34265047'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If a dose is missed, do not administer extra doses to make up the missed dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56042838"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically meaningful differences in belumosudil pharmacokinetics were observed in mild and moderate renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); consider risks versus potential benefits of initiating belumosudil in patients with severe renal impairment.</p></div>
<div class="block doha drugH1Div" id="F56042839"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment at treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Turcotte-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe impairment (Child-Turcotte-Pugh class B or C) without liver graft-versus-host disease: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 AST or ALT elevation (5 to 20 times ULN) or grade 2 bilirubin elevation (1.5 to 3 times ULN): Hold belumosudil until recovery of bilirubin, AST and ALT to grade 0 or 1, then resume belumosudil at the recommended dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 4 AST or ALT elevation (&gt;20 times ULN) or ≥ grade 3 bilirubin elevation (&gt;3 times ULN): Permanently discontinue belumosudil.</p></div>
<div class="block arsc drugH1Div" id="F56619081"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infection</b>, including serious infection, has been reported with belumosudil; however, trials involve patients with chronic graft-vs-host disease currently receiving or who previously received known immunosuppressant agents (standard of care) which are associated with an increased risk of infection, thereby making it difficult to ascertain the risk of infection associated with belumosudil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34265047','lexi-content-ref-33877856','lexi-content-ref-35135839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34265047','lexi-content-ref-33877856','lexi-content-ref-35135839'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55989496"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (27%), hypertension (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (11%), skin rash (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum calcium (12%), decreased serum phosphate (28%), increased gamma-glutamyl transferase (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (22%), decreased appetite (17%), diarrhea (35%), dysphagia (16%), nausea (42%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (11%; grades 3/4: 1%), hemorrhage (23%; grade 3/4: 5%), lymphocytopenia (29%; grades 3/4: 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacterial infection (16%), infection (53%), viral infection (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (15%), asthenia (46%), muscle spasm (17%), musculoskeletal pain (22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (30%), dyspnea (33%), nasal congestion (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum potassium (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased neutrophils (8%; grades 3/4: 4%), decreased platelet count (10%; grade 3/4: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (7%), increased serum alkaline phosphatase (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (4%)</p></div>
<div class="block coi drugH1Div" id="F55989156"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to belumosudil or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F56042820"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:0em;display:inline">There are no warnings listed in the manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F56021543"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rezurock: 200 mg</p></div>
<div class="block geq drugH1Div" id="F56021541"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56136949"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Rezurock Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $714.99</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F58086351"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rezurock: 200 mg</p></div>
<div class="block accres drugH1Div" id="F56411088"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Belumosudil is available through authorized specialty pharmacies and specialty distributors. Information is available at https://rezurockhcp.com/obtaining-rezurock/.</p></div>
<div class="block admp drugH1Div" id="F56021563"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Swallow tablets whole with a glass of water; do not cut, crush, or chew tablets. Administer with a meal at approximately the same time daily.</p></div>
<div class="block adm drugH1Div" id="F56042841"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with a meal at approximately the same time each day. Swallow whole; do not cut, crush, or chew tablets.</p></div>
<div class="block hazard drugH1Div" id="F56042823"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Belumosudil may cause teratogenicity and reproductive toxicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F56042824"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F). Dispense to patient in original container only. Store in original container to protect from moisture. Replace cap securely each time after opening. Do not discard desiccant.</p></div>
<div class="block usep drugH1Div" id="F55989470"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of chronic graft-versus-host disease after failure of at least 2 prior lines of systemic therapy (FDA approved in ages ≥12 years and adults).</p></div>
<div class="block mst drugH1Div" id="F56042816"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Belumosudil may be confused with belimumab, belinostat, budesonide.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F56026974"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C8 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor), UGT1A9; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F56026971"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Belumosudil. Management: Consider separating administration of belumosudil and antacids by 2 hours and monitor for reduced belumosudil efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Belumosudil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Belumosudil. Management: Increase the dose of belumosudil to 200 mg twice daily when coadministered with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Belumosudil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the serum concentration of Belumosudil. Management: Increase the dose of belumosudil to 200 mg twice daily when coadministered with inhibitors of the proton pump (PPIs and PCABs).<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F56042822"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;">Belumosudil C<sub>max</sub> and AUC increased 2.2 times and 2 times, respectively, following administration of a single belumosudil dose with a high-fat and high-calorie meal (800 to 1,000 calories with ~50% of calories from fat) compared to the fasted state (in healthy subjects). Management: Administer with a meal.</p></div>
<div class="block rep_considerations drugH1Div" id="F56042817"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to use in patients who may become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who may become pregnant and patients with partners who may become pregnant should use effective contraception during therapy and for 1 week after the last belumosudil dose.</p>
<p style="text-indent:0em;margin-top:2em;">Based on data from animal studies, belumosudil may reversibly impair fertility.</p></div>
<div class="block pri drugH1Div" id="F56042818"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to belumosudil may cause fetal harm.</p></div>
<div class="block mopp drugH1Div" id="F56021564"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Total bilirubin, ALT, and AST at least monthly. Verify pregnancy status prior to use in patients who may become pregnant.</p></div>
<div class="block pha drugH1Div" id="F56042825"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Belumosudil is a kinase inhibitor which selectively inhibits rho-associated, coiled-coil containing protein kinase (ROCK), predominantly inhibiting ROCK2 and to a lesser extent, ROCK1. ROCK2 inhibition downregulates signal transducer and activator of transcription 3 (STAT3) phosphorylation and decreases expression of type 17 helper T-cell (Th17) transcription factors (Cutler 2021). ROCK2 inhibition also restores immune system balance via upregulation of signal transducer and activator of transcription 5 (STAT5), which results in shifting Th17/regulatory T-cell balance (Jagasia 2021). Belumosudil inhibition of ROCK2 results in downregulation of proinflammatory responses and inhibits aberrant profibrotic signaling.</p></div>
<div class="block phk drugH1Div" id="F56042826"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 184 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99.9% (to human serum albumin); 98.6% to human alpha 1-acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily by CYP3A4 and to a lesser extent by CYP2C8, CYP2D6, and UGT1A9.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 64%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 19 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1.3 to 2.5 hours (delayed ~0.5 hours with a high-fat/high-calorie meal).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: 85% (30% as unchanged drug); urine: &lt;5%.</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 9.83 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F58865023"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: Total concentrations of AUC increased 1.4-fold, 1.5-fold, and 4.2-fold, respectively, in patients with mild, moderate, or severe impairment compared to patients with normal hepatic function. AUC of free concentrations decreased 19%, increased 1.4-fold, and increased 16-fold, respectively, in patients with mild, moderate, or severe impairment compared to patients with normal hepatic function.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34265047">
<a name="34265047"></a>Cutler CS, Lee SJ, Arai S, et al. Belumosudil for chronic graft-versus-host disease (cGVHD) after 2 or more prior lines of therapy: the ROCKstar study. <i>Blood</i>. Published online July 15, 2021. doi:10.1182/blood.2021012021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belumosudil-pediatric-drug-information/abstract-text/34265047/pubmed" id="34265047" target="_blank">34265047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33877856">
<a name="33877856"></a>Jagasia M, Lazaryan A, Bachier CR, et al. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease. <i>J Clin Oncol</i>. 2021;39(17):1888-1898. doi:10.1200/JCO.20.02754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belumosudil-pediatric-drug-information/abstract-text/33877856/pubmed" id="33877856" target="_blank">33877856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35135839">
<a name="35135839"></a>Przepiorka D, Le RQ, Ionan A, et al. FDA Approval Summary: Belumosudil for adult and pediatric patients 12 years and older with chronic GVHD after two or more prior lines of systemic therapy. <i>Clin Cancer Res</i>. Published online February 8, 2022. doi:10.1158/1078-0432.CCR-21-4176<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belumosudil-pediatric-drug-information/abstract-text/35135839/pubmed" id="35135839" target="_blank">35135839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rezurock.1">
<a name="Rezurock.1"></a>Rezurock (belumosudil) [prescribing information]. Bridgewater, NJ: Kadmon Pharmaceuticals LLC; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rezurock.2">
<a name="Rezurock.2"></a>Rezurock (belumosudil) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2016">
<a name="HHS.2016"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed July 26, 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 132099 Version 42.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
